{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:56:53Z","timestamp":1775152613290,"version":"3.50.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,6,1]]},"DOI":"10.1097\/qai.0b013e318042e204","type":"journal-article","created":{"date-parts":[[2007,5,18]],"date-time":"2007-05-18T21:43:06Z","timestamp":1179524586000},"page":"193-200","source":"Crossref","is-referenced-by-count":42,"title":["Switching to a Protease Inhibitor-Containing, Nucleoside-Sparing Regimen (Lopinavir\/Ritonavir Plus Efavirenz) Increases Limb Fat But Raises Serum Lipid Levels"],"prefix":"10.1097","volume":"45","author":[{"given":"Pablo","family":"Tebas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiameng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Yarasheski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret A","family":"Fischl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abby","family":"Shevitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Feinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann C","family":"Collier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Shikuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Brizz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Sattler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-10-20210131","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","article-title":"Cardiovascular risk and body-fat abnormalities in HIV-infected adults.","volume":"352","author":"Grinspoon","year":"2005","journal-title":"N Engl J Med"},{"key":"R2-10-20210131","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00001432-200402000-00005","article-title":"What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection.","volume":"17","author":"Tien","year":"2004","journal-title":"Curr Opin Infect Dis"},{"key":"R3-10-20210131","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/01.qai.0000182230.47819.aa","article-title":"Fat distribution in men with HIV infection.","volume":"40","author":"Bacchetti","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R4-10-20210131","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/01.aids.0000183629.20041.bb","article-title":"Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides.","volume":"19","author":"Dube","year":"2005","journal-title":"AIDS"},{"key":"R6-10-20210131","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1097\/00002030-200305020-00005","article-title":"Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy.","volume":"17","author":"Mallon","year":"2003","journal-title":"AIDS"},{"key":"R7-10-20210131","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00126334-200501010-00004","article-title":"Fat distribution in HIV-infected women in the United States: DEXA substudy in the Womens Interagency HIV Study.","volume":"38","author":"Mulligan","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R8-10-20210131","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/00002030-200107270-00008","article-title":"Clinical assessment of HIV-associated lipodystrophy in an ambulatory population.","volume":"15","author":"Lichtenstein","year":"2001","journal-title":"AIDS"},{"key":"R9-10-20210131","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1001\/archinte.162.22.2621","article-title":"Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study.","volume":"162","author":"Galli","year":"2002","journal-title":"Arch Intern Med"},{"key":"R10-10-20210131","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1097\/00002030-200009080-00025","article-title":"Is there a relationship between hepatitis C virus infection and antiretroviral-associated lipoatrophy?","volume":"14","author":"Zylberberg","year":"2000","journal-title":"AIDS"},{"key":"R11-10-20210131","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00042560-200107010-00005","article-title":"Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy.","volume":"27","author":"Duong","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R12-10-20210131","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/00126334-200303010-00018","article-title":"Hepatitis C virus in patients with HIV infection and lipodystrophy.","volume":"32","author":"Rodriguez-Guardado","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R13-10-20210131","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1097\/00002030-200210180-00005","article-title":"TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy.","volume":"16","author":"Maher","year":"2002","journal-title":"AIDS"},{"key":"R14-10-20210131","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1097\/00002030-199909100-00009","article-title":"A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.","volume":"13","author":"Saint-Marc","year":"1999","journal-title":"AIDS"},{"key":"R15-10-20210131","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","article-title":"Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet"},{"key":"R16-10-20210131","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/00002030-200007070-00002","article-title":"Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.","volume":"14","author":"Mallal","year":"2000","journal-title":"AIDS"},{"key":"R17-10-20210131","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/00002030-200105040-00005","article-title":"Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.","volume":"15","author":"van der Valk","year":"2001","journal-title":"AIDS"},{"key":"R18-10-20210131","doi-asserted-by":"crossref","first-page":"F63","DOI":"10.1097\/00002030-200003100-00005","article-title":"Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy.","volume":"14","author":"Tebas","year":"2000","journal-title":"AIDS"},{"key":"R19-10-20210131","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/01.qai.0000138420.38995.86","article-title":"Tolerability and safety of HIV protease inhibitors in adults.","volume":"37","author":"Sax","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R20-10-20210131","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/00126334-200303010-00009","article-title":"Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women.","volume":"32","author":"Justman","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R21-10-20210131","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1086\/343050","article-title":"Switching effective antiretroviral therapy: a review.","volume":"35","author":"Drechsler","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R22-10-20210131","doi-asserted-by":"crossref","first-page":"786","DOI":"10.7326\/0003-4819-140-10-200405180-00008","article-title":"Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial.","volume":"140","author":"Hadigan","year":"2004","journal-title":"Ann Intern Med"},{"key":"R23-10-20210131","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(04)15489-5","article-title":"No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.","volume":"363","author":"Carr","year":"2004","journal-title":"Lancet"},{"key":"R25-10-20210131","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/jama.288.2.207","article-title":"Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.","volume":"288","author":"Carr","year":"2002","journal-title":"JAMA"},{"key":"R26-10-20210131","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00002030-200404300-00011","article-title":"Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.","volume":"18","author":"Martin","year":"2004","journal-title":"AIDS"},{"key":"R27-10-20210131","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1086\/380790","article-title":"Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.","volume":"38","author":"McComsey","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R29-10-20210131","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S0140-6736(99)06102-4","article-title":"Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.","volume":"354","author":"Brinkman","year":"1999","journal-title":"Lancet"},{"key":"R30-10-20210131","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1086\/377311","article-title":"A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.","volume":"188","author":"Fischl","year":"2003","journal-title":"J Infect Dis"},{"key":"R31-10-20210131","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"R33-10-20210131","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1097\/00002030-200311210-00009","article-title":"Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA.","volume":"17","author":"Valantin","year":"2003","journal-title":"AIDS"},{"key":"R35-10-20210131","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/ajcn\/69.6.1162","article-title":"Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging.","volume":"69","author":"Engelson","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"R36-10-20210131","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"key":"R37-10-20210131","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAI.0b013e318042e204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:47:28Z","timestamp":1620971248000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-200706010-00010"}},"subtitle":["Results of a Prospective Randomized Trial (AIDS Clinical Trial Group 5125s)"],"short-title":[],"issued":{"date-parts":[[2007,6,1]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e318042e204","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6,1]]}}}